Tasly Pharmaceutical Group Co Ltd (600535.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE000001C81

Price
13.76 CNY
Market cap
20.55 bn CNY
P/E (2025)
18.59
P/S (2025)
2.50
Dividend yield
2.47 %
Net margin
13.42 %
Return on equity (ROE)
8.91 %
Return on assets (ROA)
7.21 %

Tasly Pharmaceutical Group Co Ltd financials

Fiscal year20242025
Revenue8.50 bn CNY8.24 bn CNY
Gross profit5.69 bn CNY5.51 bn CNY
Operating income1.08 bn CNY1.35 bn CNY
EBIT1.13 bn CNY1.34 bn CNY
Net income955.59 m CNY1.11 bn CNY
Diluted EPS – continuing operations0.64 CNY0.74 CNY

Full history since 1999, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Tasly Pharmaceutical Group Co Ltd

Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical drugs. It also engages in medical instruments, agriculture, and chain drugstore activities. The company was formerly known as Tianjin Tasly Pharmaceutical Co., Ltd. and changed its name to Tasly Pharmaceutical Group Co., Ltd in May 2012. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.